Meeting Information Requirements Throughout the Drug Development Process Rachel Buckley Director, Pr

1
Meeting Information Requirements Throughout the
Drug Development Process Rachel
BuckleyDirector, Product DevelopmentPharma/Chemi
stry MarketsThomson Scientific
2
Presentation Outline

• Overview of Diverse User Needs
• Snapshot of specific needs from customer
  research commissioned from
• Thomson Reference Architecture Strategy
• Translation into market-focused integrated
  solutions, e.g. Thomson Pharma

3
Global pharmaceutical market research project

• Objectives
• Identify relative importance of information
  product attributes to global pharmaceutical
  marketplace
• Prioritise product design, content and
  functionality to meet the needs of this market
• The Parthenon Group
• Conjoint analysis methodology
• 12,000 end user scientists and information
  professionals
• US, Europe, Asia-Pacific
• Small biotech to big pharma

4
Needs Based Segments Overall Relative Importance
of Major Attributes
of Total Respondents Scoring Attributes as
Critical
Source Customer Survey Programme n424
5
Needs Based Segments Relative Importance of
Major Attributes By Segment
of Respondents Scoring Attributes as Critical
by Segment
Note Segments were determined using K-means
cluster analysis. This examines respondents
answers to find clusters of respondents which
have similar patterns of response to the
question. The breakdown of the sample is 29 in
Segment 1, 46 in Segment 2 and 25 in Segment 3
6
Needs Based Segments Segment 1 Relative
Importance of Major Attributes
of Respondents Scoring Attributes as Critical
in Segment 1

• Segment Description
• Segment Needs
• Relatively low importance attached to information
  from a desktop product
• Emphasis on core scientific content such as
  Literature, Patents and Chemical Structure
  Information
• Low interest in commercial information such as
  Marketed Drugs, News and Company Information
• Segment Characteristics
• Segment with highest concentration of Chemists
• Few IPs in this segment

Source Customer Survey Programme n424 (Segment
1 represents 125 respondents, or 29 of the total
sample size)
7
Needs Based Segments Segment 2 Relative
Importance of Major Attributes

• Segment Description
• Segment Needs
• Relatively high importance attached to
  information available through a desktop product
• Place high importance placed on entire content
  suite
• Only segment with interest in Sequence
  Information
• Segment Characteristics
• Broad mix of Chemists, Biologists and IPs
• Segment with highest concentration of Biologists

of Respondents Scoring Attributes as Critical
in Segment 2
Source Customer Survey Programme n424 (Segment
2 represents 193 respondents, or 46 of the total
sample size)
8
Needs Based SegmentsSegment 3 Relative
Importance of Major Attributes

• Segment Description
• Segment Needs
• Low interest in core scientific information,
  especially Chemical Structure Information and
  Sequence Information
• Emphasis on commercial information such as
  Marketed Drugs, News and Company Information
• Segment Characteristics
• Very few chemists in this segment
• Majority of Clinical Trials professionals in this
  segment
• Interestingly no concentration of more senior
  people relative to other segments

of Respondents Scoring Attributes as Critical
in Segment 3
Source Customer Survey Programme n424 (Segment
3 represents 106 respondents, or 25 of the total
sample size)
9
RD Scientists Valuing attributes content
Attribute
Levels
10
RD Scientists Valuing attributes functions
Attribute
Levels
11
Product Development Prioritisation Conjoint
Attribute Utility Scores With Levels
Overall Conjoint Attribute Utility Scores with
Levels
12
. . . then identified specific workflow
information needs
Discovery
Pre-Clinical Trials
Stage of Lifecycle
Lead Identification
Lead Optimisation
Development
Step
Key Questions

• What does the target look like structurally?
• What in-vitro and in-vivo models can be used for
  screening the lead?
• Is the lead druggable?
• What previous work has been done in this area?
• What materials will be needed for
  experimentation?
• Have similar approaches been patented?

• How will the lead work within a biological
  system?
• How toxic is the lead?
• How will the lead be absorbed, distributed,
  metabolised and excreted (pharmacokinetics)?
• What previous work has been done in this area?
• What side chains can be added to improve efficacy?

• How can the lead be effectively scaled-up?
• Do we have a suitable in-vivo model to gain
  regulatory approval?
• What will be the best drug delivery method?

Information Needs

• Literature searches
• Patent information
• Chemical structure (chemoinformatics)
• Target structure (bioinformatics)
• Materials catalogues

• Literature searches
• Patent information
• Chemical information sources
• Experimental techniques

• Literature searches
• Chemical information sources
• FDA guidelines
• Patent information

Source Management interviews
13
Lifecycle Stages
Research
Discovery
Pre-Clinical Trials
Clinical Trials
Registration
Launch andSelling
Patent Expiry
Functional Areas
SCIENTIFIC
Biologists
Chemists
Clinical Researchers
LEGAL
Intellectual Property
Regulatory
Strategic Planning / Market Research / Competitor
Intelligence
COMMERCIAL
Licensing / Business Development
Marketing
Sales
Information Professionals
Source Management Interviews BCG Report
Outsell Report Parthenon analysis
14
N2 Problem
15
ThomsonPlus Concept
16
Technical architecture
Thomson Pharma Portal
Thomson Pharma DB

• Web Services
• Real time access with ability to search and
  retrieve data in XML
• Utilizes underlying functionality of each
  platform
• Avoids need for us to reload and administer the
  data centrally

17
(No Transcript)
18
Content Integration Information Associated
with
19
Content Integration

• Thomson Pharma
• 7 Key Reports
• Drug Report
• Intellectual Property Report
• Company Report
• Literature News Report
• Target Report
• Chemistry Report
• Sequence Report

• Intellectual Property Report
• Creating one record from 13 services

• Chemistry Report
• Creating one record from 6 services

• Company Report
• Creating one record from 6 services

• Drug Report
• Creating one record from 8 services

• Sequence Report
• Integrating content from 2 services

• Target Report
• Comprising over 2,200 targets

• Literature News Report
• Creating one record from 7 services

20
Master records drawing from multiple sources
21
Content consolidation into one integrated view
Breaking News NewsEdge
Overview SDdb/IDdb
Sales Market Share SDdb
Prescription Status MedStat
Biology DrugDex/WDI
Therapeutic use DrugDex
Current Development Status IDdb
Historical Development Status IDdb
Licensing IDdb
Patent Position Dolphin
Therapeutic use DrugDex
Orange Book Orange Book
Chemistry Compound Registry/IDdb
Literature Review IDdb
Scientific Data IDdb
Data Sheets Regional Detail
Asunoshinkaya Database
Find Target Target Report
Synthesis C C Reactions
References cited IDdb
Related References IDdb
22
Drug Report
Commercial perspective for launched/late stage
drugs
Full development status history
23
(No Transcript)
24

• Thomson Pharma

25
Critical Factors for Success

• Ability to search multiple global information
  sources (includes 3rd party sources, ability to
  search sources individually)
• Ability for basic and advanced searching
  (includes field searching, free-text, Boolean
  searching, proximity searching, truncation etc)
• Ability to create personalised alerting
  strategies
• Use of standard thesauri
• Standard results navigation and manipulation
  features (select multiple documents for printing,
  saving, exporting etc)
• Open architecture that makes use of standard IT
  tools and platforms supported by IM/RD IT
• User management capabilities and detailed usage
  metrics
• Financially viable business model that is
  flexible
• Appropriate content re-use rights (e.g. host
  content internally for text-mining,
  re-distribution etc)
• Flexibility to add other content (includes
  multi-level access/flexible licensing)
• Share work easily (data, analyses, approaches to
  problems solving)
• Integrated analysis tools
• High performance, ensuring stability and data
  availability in a secure environment

26
Meeting Information Requirements Throughout the
Drug Development Process Rachel
BuckleyDirector, Product DevelopmentPharma/Chemi
stry MarketsThomson Scientific